Papers

6

Total Citations

200

H-Index

5

About

Dr. Jie Yue is a leading surgical oncologist whose research centers on advancing the treatment of esophageal squamous cell carcinoma (ESCC) through minimally invasive techniques and innovative neoadjuvant strategies. Her major contributions lie in refining robot-assisted and video-assisted thoracoscopic esophagectomy, with a particular focus on the technically demanding lymph node dissection around the left recurrent laryngeal nerve—a procedure critical for reducing vocal cord palsy and pulmonary complications. Her landmark multicenter REVATE trial (56 citations) directly compares robot-assisted versus video-assisted approaches, while her learning curve study of 417 patients provides essential guidance for adopting robotic techniques. Dr. Yue also leads the Keystone-001 phase-II trial (62 citations), investigating pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy for stage III ESCC, a protocol that could reshape preoperative treatment paradigms. Her work has demonstrated that robotic approaches yield superior short-term outcomes compared to both video-assisted and open esophagectomy, with cumulative citations exceeding 200. Through these contributions, Dr. Yue is establishing evidence-based standards for surgical precision and multimodal therapy in esophageal cancer, directly impacting clinical practice in China, where over 50% of global cases occur.

Research Focus

Key Achievements

5
H-Index
6
Papers
200
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
62 citations · 2022
📈 Most Prolific Year: 2020 (3 Papers)
🤝 Key Collaborators: 32
🏛 Institutions: Tianjin Medical University Cancer Institute and Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago